Cancer Genetics, Icon Partner
News Jul 08, 2015
The partners will provide services from complex oncology genomic testing to core central laboratory analysis, project and data management, and sample logistics on a global basis. They will leverage Cancer Genetics' expertise in genomics and other technologies focused on cancer and Icon's know-how in strategic development and management, as well as the analysis of lab data from large-scale clinical programs.
The partnership is focused on providing a "comprehensive, integrated, and efficient solution for laboratory testing for global oncology trials from Phase I through Phase IV," they said in a statement.
Financial and other terms of the deal were not disclosed.
"This partnership will satisfy the enormous need among biotech and pharmaceutical companies for more efficient and comprehensive testing solutions by integrating [Cancer Genetics'] specialized, genomic testing [into] Icon's laboratory solutions," Cancer Genetics CEO Panna Sharma said.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE